Latest news articles

Added 2 months ago Drug news

AbbVie receives FDA approval of Mavyret to shorten treatment duration to eight weeks for treatment-naïve patients with chronic hepatitis C and compensated cirrhosis across all genotypes.

AbbVie announced that the FDA has granted approval of Mavyret (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to...

Added 3 months ago Drug news

FDA warning of rare cases of liver injury in HCV patients receiving Mavyret, Zepatier or Vosevi

The FDA has issued a warning about rare cases of liver injury in HCV patients receiving either AbbVie's Mavyret (glecaprevir/pibrentasvir),...

Added 5 months ago Drug news

Phase III PROTECT study of Sci-B-Vac meets endpoints in hepatitis B

VBI Vaccines announced positive top-line results from the randomized, double-blind, pivotal Phase III study, PROTECT, designed to evaluate the efficacy...

Search all news articles for Hepatitis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Guidelines

EASL Clinical Practice Guidelines on hepatitis E virus infection

Infection with hepatitis E virus (HEV) is a significant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade.

Added 1 year ago

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis.

Added 1 year ago

EASL Recommendations on Treatment of Hepatitis C 2018

These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards.

Added 1 year ago

Search all guidelines for Hepatitis
 

Journal articles

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.

Inflammation and metabolic dysfunction are hallmarks of nonalcoholic steatohepatitis (NASH), which is one of the fastest‐growing liver diseases worldwide. Emerging evidence indicates that innate immune mechanisms are pivotal...

Added 1 month ago

Reversal of NASH fibrosis with pharmacotherapy.

NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of...

Added 1 month ago

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.

Background & Aims: Little is known about outcomes of liver transplantation for patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency and outcomes of liver transplantation for patients...

Added 1 month ago

Search all journal articles for Hepatitis
 

Clinical trials

Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients

A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.

Added 1 month ago

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.

Added 1 month ago

A Phase 3/4 Clinical Study to Evaluate the Efficacy and Safety of Aramchol Versus Placebo in Subjects With NASH (ARMOR) (ARMOR)

The primary objectives of the study are to evaluate the effect of Aramchol as compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to progression of liver disease.

Added 1 month ago

Search all clinical trials for Hepatitis
 
Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where he works as a digital content manager and editor.

In his spare time, Alex enjoys relaxing with a cool pint in the company of good friends. 

ILC 2018 – Targetable pathways in liver disease: from identification to clinical application

A number of studies from the speakers at this year's ILC Basic Science Seminar are discussed here, focusing on targetable pathways in liver disease, covering pathway identification, potential drug targets and their clinical application.

CME

Abnormal liver function tests: case-based discussion

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Abnormal liver function tests: a guide to interpretation

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
90

Ascites: an unusual case: in association with Gut

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
60
Search all CME for Hepatitis